FeesSafety
Pluang+

LSEG's $3.535B Octus deal gains strong broker support, signaling potential share price growth.

Market News
23 Oct 2026
Proactive Investors
View Source
Bullish
LSEG's $3.535B Octus deal gains strong broker support, signaling potential share price growth.

London Stock Exchange Group (LSEG) secured backing from Citi, JP Morgan, and RBC Capital Markets for its $3.535 billion acquisition of Octus. Analysts praised the deal for enhancing LSEG's position in private market data and expect strong EBITDA growth from Octus. The acquisition, combined with LSEG's ongoing share buybacks and AI opportunities, supports optimistic earnings forecasts and potential share price gains. Brokers view the deal as a key driver alongside LSEG's diversified business and cash generation capabilities.

LSEG's Octus deal is the story subject, here is Pluang's Financials sector snapshot as of Oct 23, 2026 18:02 WIB: Of 142 US Financials stocks, 50 rose and 84 fell. SMFG traded at USD 23.65 with a 1-day change of -1.83%, Blackstone at USD 116.61 down 1.80%, and BBVA at USD 24.59 down 1.76%. Typical hold times vary from 8 to 97 days with mixed buy-sell activity.

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
19 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App